288 related articles for article (PubMed ID: 8825356)
1. Mechanisms of tolerance to sodium nitroprusside in rat cultured aortic smooth muscle cells.
Papapetropoulos A; Go CY; Murad F; Catravas JD
Br J Pharmacol; 1996 Jan; 117(1):147-55. PubMed ID: 8825356
[TBL] [Abstract][Full Text] [Related]
2. Lack of effect of zaprinast on methacholine-induced contraction and inositol 1,4,5-trisphosphate accumulation in bovine tracheal smooth muscle.
Chilvers ER; Giembycz MA; Challiss RA; Barnes BJ; Nahorski SR
Br J Pharmacol; 1991 May; 103(1):1119-25. PubMed ID: 1652339
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of nitrovasodilator-induced cyclic GMP accumulation in cells exposed to endotoxin or interleukin-1 beta.
Papapetropoulos A; Abou-Mohamed G; Marczin N; Murad F; Caldwell RW; Catravas JD
Br J Pharmacol; 1996 Jul; 118(6):1359-66. PubMed ID: 8832057
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effect of nitrovasodilators and cyclic GMP on ET-1-activated Ca(2+)-permeable nonselective cation channel in rat aortic smooth muscle cells.
Minowa T; Miwa S; Kobayashi S; Enoki T; Zhang XF; Komuro T; Iwamuro Y; Masaki T
Br J Pharmacol; 1997 Apr; 120(8):1536-44. PubMed ID: 9113376
[TBL] [Abstract][Full Text] [Related]
5. Effects of cyclic GMP elevation on isoprenaline-induced increase in cyclic AMP and relaxation in rat aortic smooth muscle: role of phosphodiesterase 3.
Delpy E; Coste H; Gouville AC
Br J Pharmacol; 1996 Oct; 119(3):471-8. PubMed ID: 8894166
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo interactions of nitrovasodilators and zaprinast, a cGMP-selective phosphodiesterase inhibitor.
Merkel LA; Rivera LM; Perrone MH; Lappe RW
Eur J Pharmacol; 1992 May; 216(1):29-35. PubMed ID: 1326438
[TBL] [Abstract][Full Text] [Related]
7. Relationship between cyclic guanosine monophosphate accumulation and relaxation of canine trachealis induced by nitrovasodilators.
Zhou HL; Torphy TJ
J Pharmacol Exp Ther; 1991 Sep; 258(3):972-8. PubMed ID: 1679854
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular effects of a novel, potent and selective phosphodiesterase 5 inhibitor, DMPPO: in vitro and in vivo characterization.
Delpy E; le Monnier de Gouville AC
Br J Pharmacol; 1996 Jul; 118(6):1377-84. PubMed ID: 8832060
[TBL] [Abstract][Full Text] [Related]
9. A xanthine-based KMUP-1 with cyclic GMP enhancing and K(+) channels opening activities in rat aortic smooth muscle.
Wu BN; Lin RJ; Lin CY; Shen KP; Chiang LC; Chen IJ
Br J Pharmacol; 2001 Sep; 134(2):265-74. PubMed ID: 11564644
[TBL] [Abstract][Full Text] [Related]
10. Vasorelaxant effect of isoliquiritigenin, a novel soluble guanylate cyclase activator, in rat aorta.
Yu SM; Kuo SC
Br J Pharmacol; 1995 Apr; 114(8):1587-94. PubMed ID: 7599926
[TBL] [Abstract][Full Text] [Related]
11. Evidence that additional mechanisms to cyclic GMP mediate the decrease in intracellular calcium and relaxation of rabbit aortic smooth muscle to nitric oxide.
Weisbrod RM; Griswold MC; Yaghoubi M; Komalavilas P; Lincoln TM; Cohen RA
Br J Pharmacol; 1998 Dec; 125(8):1695-707. PubMed ID: 9886761
[TBL] [Abstract][Full Text] [Related]
12. In vivo depletion of free thiols does not account for nitroglycerin-induced tolerance: a thiol-nitrate interaction hypothesis as an alternative explanation for nitroglycerin activity and tolerance.
Haj-Yehia AI; Benet LZ
J Pharmacol Exp Ther; 1996 Sep; 278(3):1296-305. PubMed ID: 8819515
[TBL] [Abstract][Full Text] [Related]
13. Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators.
Mülsch A; Bauersachs J; Schäfer A; Stasch JP; Kast R; Busse R
Br J Pharmacol; 1997 Feb; 120(4):681-9. PubMed ID: 9051308
[TBL] [Abstract][Full Text] [Related]
14. Actions of 3-morpholinosydnonimin (SIN-1) on rabbit isolated penile erectile tissue.
Holmquist F; Fridstrand M; Hedlund H; Andersson KE
J Urol; 1993 Oct; 150(4):1310-5. PubMed ID: 8396690
[TBL] [Abstract][Full Text] [Related]
15. Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity.
Galle J; Zabel U; Hübner U; Hatzelmann A; Wagner B; Wanner C; Schmidt HH
Br J Pharmacol; 1999 May; 127(1):195-203. PubMed ID: 10369473
[TBL] [Abstract][Full Text] [Related]
16. Contribution of phosphodiesterase isoenzymes and cyclic nucleotide efflux to the regulation of cyclic GMP levels in aortic smooth muscle cells.
Mercapide J; Santiago E; Alberdi E; Martinez-Irujo JJ
Biochem Pharmacol; 1999 Nov; 58(10):1675-83. PubMed ID: 10535760
[TBL] [Abstract][Full Text] [Related]
17. Involvement of cyclic nucleotide-dependent protein kinases in cyclic AMP-mediated vasorelaxation.
Eckly-Michel A; Martin V; Lugnier C
Br J Pharmacol; 1997 Sep; 122(1):158-64. PubMed ID: 9298542
[TBL] [Abstract][Full Text] [Related]
18. Effect of cyclic GMP-dependent vasodilators on the expression of inducible nitric oxide synthase in vascular smooth muscle cells: role of cyclic AMP.
Boese M; Busse R; Mülsch A; Schini-Kerth V
Br J Pharmacol; 1996 Oct; 119(4):707-15. PubMed ID: 8904645
[TBL] [Abstract][Full Text] [Related]
19. Phosphodiesterase isozyme inhibition and the potentiation by zaprinast of endothelium-derived relaxing factor and guanylate cyclase stimulating agents in vascular smooth muscle.
Harris AL; Lemp BM; Bentley RG; Perrone MH; Hamel LT; Silver PJ
J Pharmacol Exp Ther; 1989 May; 249(2):394-400. PubMed ID: 2566675
[TBL] [Abstract][Full Text] [Related]
20. Zaprinast, but not dipyridamole, reverses hemodynamic tolerance to nitroglycerin in vivo.
De Garavilla L; Pagani ED; Buchholz RA; Dundore R; Bode DC; Volberg ML; Jackson KN; Pratt P; Silver PJ
Eur J Pharmacol; 1996 Oct; 313(1-2):89-96. PubMed ID: 8905333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
